WO2018104877A1 - Compositions comprising boswellia sacra for the treatment of benign prostatic hyperplasia - Google Patents
Compositions comprising boswellia sacra for the treatment of benign prostatic hyperplasia Download PDFInfo
- Publication number
- WO2018104877A1 WO2018104877A1 PCT/IB2017/057681 IB2017057681W WO2018104877A1 WO 2018104877 A1 WO2018104877 A1 WO 2018104877A1 IB 2017057681 W IB2017057681 W IB 2017057681W WO 2018104877 A1 WO2018104877 A1 WO 2018104877A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- boswellia sacra
- compositions
- zinc
- treatment
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Definitions
- the present invention concerns the field of compositions containing natural active ingredients, in particular Boswellia Sacra, and the formulations for oral administration containing them.
- BPH benign prostatic hypertrophy
- BPH represents one of the most common pathologies in adult men; 50 % of men aged 50-60 years and 90% of men of average age 80 years suffer from a stage that requires therapy (1 ), after 70 years the percentage increases: 8 out of 10 men suffer from this.
- the pathology begins as structural modification of the gland, already around 30 years of age, but it generally clinically manifests itself after 40 years of age. The older one gets, the more often it occurs.
- the daily problem often the source of worry, anxiety and serious discomfort for young or older men, is "counterbalanced" with some good news, which must not overshadow the checks: BPH cannot degenerate into prostatic neoplasia.
- the harmful alterations of the bladder muscle are slow and chronic, firstly reversible, then irreversible. Initially they appear with difficulty in urinating that coincides with problematic emptying of the bladder, with impulsive stimuli and the daily and nightly increase of stream hesitancy. With the obstructive phase there is reduction, difficulty in starting urination and incomplete emptying of the bladder.
- the therapy can, however, only be effective after at least 3 months of treatment and the essential element is the reduction of production by the body of the enzyme 5- alpha reductase and moreover it is worth remembering that the plant is capable of giving relief only from the functional disturbances caused by BPH, but is unable to reduce the size of the prostate.
- compositions containing Boswellia sacra and their use for the treatment of benign prostatic hyperplasia.
- compositions containing Boswellia sacra in combination with Serenoa repens, Vitamin D3 and zinc allow the effective treatment of BPH, thus overcoming the aforementioned problems.
- Boswellia sacra potently inhibits the growth of human prostate tumour through the inhibition of angiogenesis induced by signaling pathways VEGFR2.
- Vitamin D can regulate the proliferation, apoptosis, and cellular differentiation towards tumour cells: supplementing with vitamin D is therefore important to prevent the occurrence of prostate cancer and/or the progression of the tumour in the patient suffering from this tumour.
- Zinc reduces the secretion of prolactin and prolactin increases the intake of testosterone in the prostate, the intake of this mineral determines a reduction of the level of prostatic DHT which makes it possible to obtain particularly interesting results in the treatment of benign prostatic hyperplasia.
- the synergic activity of this composition ensures a clear reduction of obstructive symptoms (difficulty in starting urination or dysuria, intermittent stream, incomplete emptying of the bladder, weak stream and effort required for urination), irritative symptoms (pollakiuria and nocturia - increased frequency of urination and increased need to urinate during the night, respectively), urgency (since the need to empty the bladder cannot be delayed) burning during urination, perineal tension.
- obstructive symptoms difficulty in starting urination or dysuria, intermittent stream, incomplete emptying of the bladder, weak stream and effort required for urination
- irritative symptoms polylakiuria and nocturia - increased frequency of urination and increased need to urinate during the night, respectively
- urgency since the need to empty the bladder cannot be delayed burning during urination, perineal tension.
- Serenoa repens is meant to indicate the sterol lipid extract obtained by extraction with C02 and with high titer in fatty acids (85%)
- Boswellia sacra is meant to indicate a fluid extract of gum-resins containing >40 gr/Kg of AKBA and > 30 gr/Kg of ⁇ - ⁇ + ⁇ - ⁇ + ⁇ .
- the volatile fraction contains cembranoid diterpenes, incensole and incensole acetate with quantity > 65 gr/Kg.
- This type of boswellia represents the only available source of liquid extracts of gum-resins of Boswellia sacra capable of providing a unique series of applications: greater solubility, non-ethanolic formulation, greater bioavailability, high content of volatile compounds with bioactive properties (incensole acetate).
- Zinc is normally present in salt form like for example monoanhydrous sulphate
- composition according to the invention can also contain other active ingredients like for example selenium.
- the aforementioned components are present in the following percentages calculated over the total weight of the composition:
- Boswellia sacra 10 - 35%
- Vitamin D3 0.005 - 0.60%
- a particularly preferred composition consists of : Serenoa Repensa 74.840%
- Vitamin D3 0.002%
- compositions according to the invention are formulated in the form of soft capsules thus consisting of the oily liquid content consisting of the aforementioned active ingredients and possible excipients and an outer casing normally consisting of bovine gelatin, glycerine, titanium dioxide and possibly suitable dyes.
- the final soft capsules have a weight of between 700 and 1 300 mg.
- the soft capsules and the technology for producing them are well known and make it possible to obtain an excellent bioavailability and stability of the active ingredients and greater speed of action since the casing breaks within a few minutes releasing the substances, which become available more quickly and in this way also the absorption in the intestine is quicker with respect to solid formulations.
- the preparation process essentially provides for the solubilisation of the zinc salt and of the selenium with the oils of Serenoa repens, Boswellia sacra and Vitamin D3 and then the injection of said mixture in the capsules during their formation.
- the composition obtained is loaded into a colloid mill, consisting of a frusto-conical rotor that rotates, at extremely high speed, inside a stator.
- the distance between rotor and stator can be adjusted so as to obtain the desired consistency of the emulsion: all of this always at controlled temperature.
- This process reduces the size of the particles of the emulsion to about 0.65 mm, once the texture of the mixture has been approved this is then introduced into the tank to then pass to the encapsulation step,
- the reactor is loaded with 60 % of the Glycerine necessary to make the softgels (24.5 kg), Titanium dioxide (1 .8 kg) and chlorophyll (0.239Kg), mixing the components for 30 minutes: then the remaining glycerine (16.3 kg) and the gelatin (88.8 kg) is loaded and the mixing is continued for another 20 minutes.
- the resulting composition is passed through a sieve with porosity of 1 mm.
- the product thus obtained is transported in containers at controlled temperature of
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention describes compositions containing Boswellia sacra and formulations thereof in the form of soft capsules useful for the treatment of benign prostatic hyperplasia.
Description
COMPOSITIONS COMPRISING BOSWELLIA SACRA FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Field of the invention
The present invention concerns the field of compositions containing natural active ingredients, in particular Boswellia Sacra, and the formulations for oral administration containing them.
State of the art
As it is known benign prostatic hypertrophy (BPH) is a pathology characterised by the increase in size of the prostate gland due to a benign growth of its tissue, caused by different factors but mainly by the stimulation of androgenic steroid hormones (dihydrotestosterone) and of oestrogens.
BPH represents one of the most common pathologies in adult men; 50 % of men aged 50-60 years and 90% of men of average age 80 years suffer from a stage that requires therapy (1 ), after 70 years the percentage increases: 8 out of 10 men suffer from this.
The pathology begins as structural modification of the gland, already around 30 years of age, but it generally clinically manifests itself after 40 years of age. The older one gets, the more often it occurs. The daily problem, often the source of worry, anxiety and serious discomfort for young or older men, is "counterbalanced" with some good news, which must not overshadow the checks: BPH cannot degenerate into prostatic neoplasia. The harmful alterations of the bladder muscle are slow and chronic, firstly reversible, then irreversible. Initially they appear with difficulty in urinating that coincides with problematic emptying of the bladder, with impulsive stimuli and the daily and nightly increase of stream hesitancy. With the obstructive phase there is reduction, difficulty in starting urination and incomplete emptying of the bladder.
If the prostate volume exceeds 40 cc with a total PSA greater than 1 .4 ng/ml use is made initially of drugs like alpha-1 receptor inhibitors with which another class of drugs is associated: 5 alpha reductase inhibitors that really act on the growth of BPH blocking it and thus preventing a progression thereof up to the development of
complications.
For the inflammation problems that affect the prostate there are also therapies based on vegetable extracts mainly with Serenoa Repens.
The therapy can, however, only be effective after at least 3 months of treatment and the essential element is the reduction of production by the body of the enzyme 5- alpha reductase and moreover it is worth remembering that the plant is capable of giving relief only from the functional disturbances caused by BPH, but is unable to reduce the size of the prostate.
It is thus clear how it is necessary to make new preparations capable of carrying out the desired action more efficiently.
Summary of the invention
The invention describes compositions containing Boswellia sacra and their use for the treatment of benign prostatic hyperplasia.
Detailed description of the invention
It has now surprisingly been found that compositions containing Boswellia sacra in combination with Serenoa repens, Vitamin D3 and zinc allow the effective treatment of BPH, thus overcoming the aforementioned problems.
In particular, Boswellia sacra (AKBA) potently inhibits the growth of human prostate tumour through the inhibition of angiogenesis induced by signaling pathways VEGFR2.
Moreover, the important anti-inflammation activity and the counteraction of localised muscle tension states improve urination by acting on the muscle fibres present in prostate tissue. The latest evidence from international literature also highlights how the role of inflammation is essential as hyperplasia-triggering factor: the anti- inflammation and anti-swelling action of Boswellia Sacra contribute to the reduction of cell proliferation, activating cellular apoptosis.
Vitamin D can regulate the proliferation, apoptosis, and cellular differentiation towards tumour cells: supplementing with vitamin D is therefore important to prevent the occurrence of prostate cancer and/or the progression of the tumour in the patient suffering from this tumour.
Zinc reduces the secretion of prolactin and prolactin increases the intake of testosterone in the prostate, the intake of this mineral determines a reduction of the level of prostatic DHT which makes it possible to obtain particularly interesting results in the treatment of benign prostatic hyperplasia.
The synergic activity of this composition ensures a clear reduction of obstructive symptoms (difficulty in starting urination or dysuria, intermittent stream, incomplete emptying of the bladder, weak stream and effort required for urination), irritative symptoms (pollakiuria and nocturia - increased frequency of urination and increased need to urinate during the night, respectively), urgency (since the need to empty the bladder cannot be delayed) burning during urination, perineal tension.
According to the invention the term Serenoa repens is meant to indicate the sterol lipid extract obtained by extraction with C02 and with high titer in fatty acids (85%) The term Boswellia sacra is meant to indicate a fluid extract of gum-resins containing >40 gr/Kg of AKBA and > 30 gr/Kg of α-ΒΑ+β-ΒΑ+ΚΒΑ.
The volatile fraction contains cembranoid diterpenes, incensole and incensole acetate with quantity > 65 gr/Kg. This type of boswellia represents the only available source of liquid extracts of gum-resins of Boswellia sacra capable of providing a unique series of applications: greater solubility, non-ethanolic formulation, greater bioavailability, high content of volatile compounds with bioactive properties (incensole acetate).
Zinc is normally present in salt form like for example monoanhydrous sulphate
The composition according to the invention can also contain other active ingredients like for example selenium.
Normally, the aforementioned components are present in the following percentages calculated over the total weight of the composition:
Serenoa repens: 60 - 85%
Boswellia sacra: 10 - 35%
Vitamin D3: 0.005 - 0.60%
Zinc: 3 - 10%
Selenium 0.005 - 0.060%
A particularly preferred composition, according to the present invention, consists of :
Serenoa Repensa 74.840%
Boswellia Sacra 18.710%
Vitamin D3 0.002%
Zinc 6.420%
Selenium 0.028%
Normally, the compositions according to the invention are formulated in the form of soft capsules thus consisting of the oily liquid content consisting of the aforementioned active ingredients and possible excipients and an outer casing normally consisting of bovine gelatin, glycerine, titanium dioxide and possibly suitable dyes.
Normally, the final soft capsules have a weight of between 700 and 1 300 mg.
The soft capsules and the technology for producing them are well known and make it possible to obtain an excellent bioavailability and stability of the active ingredients and greater speed of action since the casing breaks within a few minutes releasing the substances, which become available more quickly and in this way also the absorption in the intestine is quicker with respect to solid formulations.
The preparation process essentially provides for the solubilisation of the zinc salt and of the selenium with the oils of Serenoa repens, Boswellia sacra and Vitamin D3 and then the injection of said mixture in the capsules during their formation.
Example 1
Production batch for 600,000 softgel of 701 mg. cad.
a) Preparation of the oily suspension to be inserted inside the softgel:
24 kg of sunflower oil is introduced into a reactor and it is heated to a temperature of
65°C; immediately after, again inside the reactor, reducing the temperature to 60°C the following are mixed: Serenoa repens (192 kg), zinc (7.2 kg), Vitamin D (0.24 kg), Boswellia Sacra (48 Kg) and selenium (0.072 Kg) with the emulsifiers: sunflower lecithin (6kg) and white beeswax (10.8 kg).
Immediately after, the mixture is cooled to a temperature of 25°C and again inside the reactor, it is mixed under vacuum for 120 minutes always keeping a controlled temperature of 25°C.
The composition obtained is loaded into a colloid mill, consisting of a frusto-conical rotor that rotates, at extremely high speed, inside a stator.
The distance between rotor and stator can be adjusted so as to obtain the desired consistency of the emulsion: all of this always at controlled temperature.
This process reduces the size of the particles of the emulsion to about 0.65 mm, once the texture of the mixture has been approved this is then introduced into the tank to then pass to the encapsulation step,
b) Encapsulation step
The reactor is loaded with 60 % of the Glycerine necessary to make the softgels (24.5 kg), Titanium dioxide (1 .8 kg) and chlorophyll (0.239Kg), mixing the components for 30 minutes: then the remaining glycerine (16.3 kg) and the gelatin (88.8 kg) is loaded and the mixing is continued for another 20 minutes.
At this point purified water at a temperature of 5°C is loaded into the reactor and then the temperature of the reactor is raised to 80°C to melt the mass, then continuing to mix for 2 hours, under vacuum.
The resulting composition is passed through a sieve with porosity of 1 mm.
The product thus obtained is transported in containers at controlled temperature of
65°C towards the machine for making the softgels.
Claims
1 . Compositions containing Boswellia sacra in combination with Serenoa repens, Vitamin D3 and zinc, and possibly selenium.
2. A composition according to claim 1 , wherein said Serenoa repens is the sterol lipid extract obtained by extraction with C02 with titer of at least 85% of fatty acids.
3. A composition according to claims 1 and 2, wherein said Boswellia sacra is the fluid extract of gum-resins containing >40 gr/Kg AKBA and ≥ 30 gr/Kg α-ΒΑ+β- BA+KBA.
4. A composition according to claims 1 - 3, wherein zinc is present in salt form.
5. A composition according to any one of claims 1 - 4, consisting of:
Serenoa repens: 60 - 85%
Boswellia sacra: 10 - 35%
Vitamin D3: 0.005 - 0.60%
Zinc: 3 - 10%
Selenium 0.005 - 0.060%
where said percentages are calculated on the total weight of the composition.
6. A composition according to claim 5, consisting of:
Serenoa Repensa 74.840%
Boswellia Sacra 18.710%
Vitamin D3 0.002%
Zinc 6.420%
Selenium 0.028%
where said percentages are calculated on the total weight of the composition.
7. Compositions according to claims 1 - 6 formulated in the form of soft capsules.
8. Compositions according to claim 7, wherein said soft capsules have a weight from 700 to 1300 mg.
9. Compositions according to claims 1 - 6 for use in the treatment of benign prostatic hypertrophy.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102016000124361A IT201600124361A1 (en) | 2016-12-07 | 2016-12-07 | Compositions containing Boswellia Sacra for the treatment of benign prostatic hyperplasia |
| IT102016000124361 | 2016-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018104877A1 true WO2018104877A1 (en) | 2018-06-14 |
Family
ID=58545075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2017/057681 Ceased WO2018104877A1 (en) | 2016-12-07 | 2017-12-06 | Compositions comprising boswellia sacra for the treatment of benign prostatic hyperplasia |
Country Status (2)
| Country | Link |
|---|---|
| IT (1) | IT201600124361A1 (en) |
| WO (1) | WO2018104877A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6200573B1 (en) * | 1999-12-03 | 2001-03-13 | Starcor Pharmaceuticals, Inc. | Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia |
| US20020001633A1 (en) * | 1999-09-10 | 2002-01-03 | Chase Revel | Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer |
| WO2009103477A1 (en) * | 2008-02-22 | 2009-08-27 | Indena S.P.A. | Compositions for the treatment of benign prostate hypertrophy, prostatitis, prostatosis and prostate cancer |
-
2016
- 2016-12-07 IT IT102016000124361A patent/IT201600124361A1/en unknown
-
2017
- 2017-12-06 WO PCT/IB2017/057681 patent/WO2018104877A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020001633A1 (en) * | 1999-09-10 | 2002-01-03 | Chase Revel | Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer |
| US6200573B1 (en) * | 1999-12-03 | 2001-03-13 | Starcor Pharmaceuticals, Inc. | Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia |
| WO2009103477A1 (en) * | 2008-02-22 | 2009-08-27 | Indena S.P.A. | Compositions for the treatment of benign prostate hypertrophy, prostatitis, prostatosis and prostate cancer |
Non-Patent Citations (3)
| Title |
|---|
| A AL-HARRASI ET AL: "Antiglycation and Antioxidant Activities and HPTLC Analysis of <i>Boswellia sacra</i> Oleogum Resin: The Sacred Frankincense", TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, vol. 12, no. 4, 28 August 2013 (2013-08-28), pages 597 - 602, XP055199042, ISSN: 1596-5996, DOI: 10.4314/tjpr.v12i4.23 * |
| PAN YING-NI ET AL: "Comparative studies of pharmacokinetics and anticoagulatory effect in rats after oral administration of Frankincense and its processed products", JOURNAL OF ETHNOPHARMACOLOGY, vol. 172, 25 June 2015 (2015-06-25), pages 118 - 123, XP029252937, ISSN: 0378-8741, DOI: 10.1016/J.JEP.2015.06.029 * |
| XIAO NI ET AL: "Frankincense essential oil prepared from hydrodistillation of Boswellia sacra gum resins induces human pancreatic cancer cell death in cultures and in a xenograft murine model", BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, BIOMED CENTRAL LTD., LONDON, GB, vol. 12, no. 1, 13 December 2012 (2012-12-13), pages 253, XP021135926, ISSN: 1472-6882, DOI: 10.1186/1472-6882-12-253 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IT201600124361A1 (en) | 2018-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Muradian et al. | Fucoxanthin and lipid metabolism: A minireview | |
| JP2020502040A (en) | Method for selectively extracting cannabinoids from plant sources | |
| EP2968137B1 (en) | Emulsion formulations | |
| EP2722038A2 (en) | Lipid Composition | |
| AU2017279694B2 (en) | Herbal Compositions for the Prevention or Treatment of Benign Prostatic Hyperplasia and Related Disorders | |
| JP2015013888A (en) | Methods and compounds for vitamin d therapy | |
| WO2007124598A2 (en) | Softgel capsules with phytosterols and/or phytostanols and optionlly omega polyunstaurated fatty acids | |
| KR20010040776A (en) | Method and Composition for Treatment of Inflammatory Conditions | |
| AU2018361636A1 (en) | A dietary composition comprising plant-based sources of fatty acids | |
| US20210369737A1 (en) | Prostate function support formula | |
| WO2018104877A1 (en) | Compositions comprising boswellia sacra for the treatment of benign prostatic hyperplasia | |
| JP2019504117A (en) | Pharmaceutical composition for the treatment of prostate hyperplasia | |
| CN103461540B (en) | Functional fat with effect of preventing disease of prostate and preparation method thereof | |
| CN119097578B (en) | Silk fibroin emulsion containing oryzanol and application thereof | |
| US20050153948A1 (en) | Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone | |
| CN103054025A (en) | Health-care food composition for preventing and treating prostate disease | |
| Wani et al. | Healing with herbs: A systematic review of natural treatments for polycystic ovary syndrome | |
| US20220105107A1 (en) | Bioidentical progesterone cream infused with nanoemulsified cbd | |
| RU2574014C2 (en) | Method for preventing and treating benign prostatic hyperplasia | |
| CN112336705A (en) | Preparation method and application of artificial cannabidiol chyle | |
| JP6134953B2 (en) | Fruit-derived compounds of Acrocomia crispa and Acrocomia acreata against inflammation and oxidative stress | |
| AU2019395549B2 (en) | Composition comprising dutasteride | |
| CN108434358A (en) | A kind of alimentation composition and its preparation method and application with neuroprotection | |
| IT202100011210A1 (en) | COMBINATION COMPOSITION FOR THE PREVENTION AND TREATMENT OF PROSTATE AND UROLOGICAL DISORDERS | |
| Abdel-Kareem et al. | The ameliorative effects of propolis and/or levothyroxine on propylthiouracil-induced hypothyroidism in adult albino rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17825611 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 27.09.2019) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17825611 Country of ref document: EP Kind code of ref document: A1 |